No

Anticholinergic Agent; Antiemetic

Control of nausea and vomiting (especially for long-term antiemetic therapy); less effective than phenothiazines but may be associated with fewer side effects

C

Hypersensitivity to trimethobenzamide, benzocaine, or any component; injection contraindicated in children and suppositories are contraindicated in premature infants or neonates

May mask emesis due to Reye's syndrome or mimic CNS effects of Reye's syndrome in patients with emesis of other etiologies; use in patients with acute vomiting should be avoided

>10%: Central nervous system: Drowsiness

1% to 10%:

Cardiovascular: Hypotension

Central nervous system: Dizziness, headache

Gastrointestinal: Diarrhea

Neuromuscular & skeletal: Muscle cramps

<1%: Mental depression, convulsions, opisthotonus, hypersensitivity skin reactions, blood dyscrasias, hepatic impairment

Symptoms of overdose include hypotension, seizures, CNS depression, cardiac arrhythmias, disorientation, confusion

Following initiation of essential overdose management, toxic symptom treatment and supportive treatment should be initiated. Hypotension usually responds to I.V. fluids or Trendelenburg positioning. If unresponsive to these measures, the use of a parenteral inotrope may be required (eg, norepinephrine 0.1-0.2 mcg/kg/minute titrated to response). Seizures commonly respond to diazepam (I.V. 5-10 mg bolus in adults every 15 minutes, if needed, up to a total of 30 mg; I.V. 0.25-0.4 mg/kg/dose up to a total of 10 mg in children) or to phenytoin or phenobarbital. Critical cardiac arrhythmias often respond to lidocaine 1-2 mg/kg bolus followed by a maintenance infusion. Extrapyramidal symptoms (eg, dystonic reactions) may be managed with diphenhydramine 1-2 mg/kg (adults) up to a maximum of 50 mg I.M. or I.V. slow push followed by a maintenance dose for 48-72 hours. When these reactions are unresponsive to diphenhydramine, benztropine mesylate I.V. 1-2 mg (adults) may be effective. These agents are generally effective within 2-5 minutes.

Antagonism of oral anticoagulants may occur

Store injection at room temperature; protect from heat and from freezing; use only clear solutions

Acts centrally to inhibit the medullary chemoreceptor trigger zone

Onset of antiemetic effect: Oral: Within 10-40 minutes; I.M.: Within 15-35 minutes

Duration: 3-4 hours

Absorption: Rectal: ~60%

Rectal use is contraindicated in neonates and premature infants

Rectal: <14 kg: 100 mg 3-4 times/day

Oral, rectal: 14-40 kg: 100-200 mg 3-4 times/day

Adults:

Oral: 250 mg 3-4 times/day

I.M., rectal: 200 mg 3-4 times/day

Administer I.M. only

Drowsiness is common; may cause dizziness; may rarely cause depression

Concurrent use with psychotropics may produce additive sedation

No information available to require special precautions

No effects or complications reported

Take as directed before meals; do not increase dose and do not discontinue without consulting prescriber. You may experience drowsiness or blurred vision (use caution when driving or engaging in tasks that require alertness until response to drug is known) or diarrhea (buttermilk or yogurt may help). Report chest pain or palpitations, persistent dizziness or blurred vision, or CNS changes (disorientation, depression, confusion). Pregnancy/breast-feeding precautions: Inform prescriber if you are or intend to be pregnant. Consult prescriber if breast-feeding.

Use only clear solution; observe for extrapyramidal and anticholinergic effects

Capsule, as hydrochloride: 100 mg, 250 mg

Injection, as hydrochloride: 100 mg/mL (2 mL, 20 mL)

Suppository, rectal, as hydrochloride: 100 mg, 200 mg